Omadacycline for Community-Acquired Bacterial Pneumonia.

Area of Science:

• Infectious Diseases
• Pulmonology
• Pharmacology

Background:

• Omadacycline is a novel, once-daily aminomethylcycline antibiotic with intravenous and oral formulations.
• It achieves high pulmonary tissue concentrations and exhibits activity against pathogens causing community-acquired bacterial pneumonia (CABP).

Purpose of the Study:

• To evaluate the noninferiority of omadacycline compared to moxifloxacin in treating adults with CABP.
• To assess early and post-treatment clinical response rates and safety profiles of both agents.

Main Methods:

• A double-blind, randomized trial comparing omadacycline and moxifloxacin in adults with CABP (Pneumonia Severity Index risk class II-IV).
• Patients received intravenous treatment, with an option to switch to oral therapy. Total treatment duration was 7-14 days.
• Primary endpoint: early clinical response at 72-120 hours. Secondary endpoint: investigator-assessed clinical response post-treatment.

Main Results:

• Omadacycline was noninferior to moxifloxacin for early clinical response (81.1% vs. 82.7%) and post-treatment clinical response (87.6% vs. 85.1%).
• Adverse events were less frequent with omadacycline (41.1%) compared to moxifloxacin (48.5%), particularly gastrointestinal events and diarrhea.
• Twelve deaths occurred during the trial (8 in the omadacycline group, 4 in the moxifloxacin group).

Conclusions:

• Omadacycline is a noninferior treatment option to moxifloxacin for adults with community-acquired bacterial pneumonia.
• The study supports omadacycline's efficacy and a potentially favorable safety profile in CABP treatment.